Robert Hamilton on The Recent Announcement from Philips and Royal London Hospital
Robert Hamilton, Chief Executive Officer of NeuraSignal, shared on LinkedIn:
”The recent announcement from Philips and Royal London Hospital represents exactly the kind of forward progress our field needs: rethinking the entire stroke pathway, not just optimizing one step of it.
What stood out to me in this work is the focus on workflow redesign.
Stroke care is a chain of time-critical decisions, and the strength of that chain depends on how well clinical teams, technology, and operational processes are aligned.
When organizations take a system-wide approach like Philips and Barts Health NHS Trust have done here, the impact reaches far beyond any single device or modality.
For those of us working in neurovascular innovation, efforts like this matter.
They signal a broader shift toward integrated, data-driven stroke care where imaging, monitoring, automation, and clinical insight work together rather than in isolation.
It’s the kind of environment where technologies like automated cerebral blood flow monitoring can meaningfully contribute and where collaboration across companies and clinical teams can raise the standard of care as a whole.
Congratulations to the teams at Philips, Barts Health, and Royal London Hospital.
Redesigning a pathway is hard work, but it’s the kind of work that changes outcomes.
Read the full story here.
Also great to see Dr Paul Bhogal and his excellent work.”

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series